ADVFN US – Market Content Editor
-
Lear Shares Drop Nearly 10% After Q2 Earnings Miss Despite Revenue Beat
Lear Corporation (NYSE:LEA), a leading name in automotive technology, reported second-quarter earnings that fell short of analyst expectations on Friday, even though revenue slightly surpassed forecasts. Following the earnings release, Lear’s stock plunged 9.83% in pre-market trading. The company posted earnings per share of $3.06 for Q2, missing the analyst consensus of $3.26 by 20…
-
Eli Lilly’s Alzheimer’s Drug Kisunla Receives Positive CHMP Recommendation
Eli Lilly (NYSE:LLY) announced that its Alzheimer’s medication Kisunla (donanemab) has secured a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The committee recommended Kisunla for treating early symptomatic Alzheimer’s disease. Following the CHMP’s endorsement, the European Commission is expected to issue a final regulatory decision on donanemab…
-
Portland General Electric Surpasses Q2 Estimates on Rising Data Center Demand
On Friday, Portland General Electric Company (NYSE:POR) announced second-quarter adjusted earnings of $0.66 per share, beating analyst forecasts of $0.64. This strong result was driven by a 16.5% quarter-over-quarter surge in demand, largely attributed to growth in data center industrial loads. Revenue totaled $807 million, outpacing the consensus estimate of $794.08 million. Following the announcement,…
-
Centene Shares Drop 10% Following Unexpected Quarterly Loss
Centene (NYSE:CNC) reported a surprise quarterly loss on Friday, citing revenue declines linked to its government-sponsored health programs, which led to a significant earnings shortfall. The health insurer’s stock fell more than 10% in premarket trading. Centene recorded a second-quarter loss of $0.16 per share, well below analyst estimates of earnings of $0.39 per share.…
-
Aon Surpasses Q2 Earnings Estimates on Robust Revenue Growth
Aon plc delivered second-quarter 2025 adjusted earnings that beat analyst forecasts, supported by solid organic revenue expansion across its divisions and enhanced operational efficiencies. The company reported adjusted earnings per share of $3.49, exceeding the consensus estimate of $3.40. Total revenue rose by 11% to $4.16 billion, just shy of the expected $4.17 billion, while…
-
Carter’s Misses Q2 EPS Expectations Despite Revenue Beat; Profitability Takes a Hit
Carter’s Inc (NYSE:CRI), a leading children’s clothing retailer, delivered mixed second-quarter results on Friday, reporting earnings that fell short of analyst projections even as revenue surpassed expectations. The earnings release comes as the company adjusts to new leadership and grapples with a profitability squeeze. The company posted adjusted earnings per share of $0.17, falling well…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures Inch Higher as Market Digests Earnings; Intel, Centene Sink, Deckers Jumps
U.S. stock futures ticked up Friday morning, supported by a mostly upbeat earnings season even as several major names posted sharp premarket moves. Investors are also turning their attention to the Federal Reserve’s upcoming policy meeting next week. Here’s a rundown of the key premarket movers: With big tech earnings and the Fed decision looming,…
-
Intel shares fall sharply after announcing job cuts and posting unexpected Q2 earnings
Intel (NASDAQ:INTC) provided optimistic revenue guidance for the upcoming quarter after delivering second-quarter revenue results that exceeded analyst forecasts. However, the semiconductor giant warned that earnings took a hit due to write-downs connected to scaling back plans for new chip manufacturing facilities. The company also disclosed a workforce reduction plan, aiming to cut staff by…
-
Dollar Inches Upward as Markets Eye Upcoming Fed Meeting
On Friday, the U.S. dollar climbed modestly, recovering from a two-week low, but it remains on shaky ground as investors assess the evolving global trade environment ahead of next week’s Federal Reserve policy meeting. At 04:35 ET (08:35 GMT), the Dollar Index, which measures the dollar’s value against a basket of six currencies, edged up…
-
Positive CHMP Opinion for Gilead’s Lenacapavir in HIV Prevention
Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for lenacapavir to be used as pre-exposure prophylaxis (PrEP) against HIV. This accelerated review endorses lenacapavir to lower the risk of sexually transmitted HIV-1 infection in adults and adolescents considered at…